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Abstract
Background: The impact of poison information services on patient care in hospital,
particularly decisions onwhether to admit patients after initial attendance at an emer-
gency department (ED), is unclear. In the United Kingdom, the vast majority of poisons
information is provided by use of the online poisons information database, TOXBASE.
We investigated the relationship between rates of hospital access to TOXBASE and
rates of poisoning admissions from EDs in England and Wales to begin to address the
interactions between use of poisons information and patientmanagement as reflected
by hospital activity.
Methods: Data were obtained on attendances and admissions due to poisoning for
individual National Health Service (NHS) Trusts in both England and Wales, together
with data on the overall number of accesses to TOXBASE for drugs (pharmaceuticals
and drugs of abuse), from 2008 to 2015. Rates of TOXBASE access and admissions
per poisoning attendance in London were clearly different to the rest of England and
Wales; Londonwas therefore analyzed separately. Negative binomial generalized addi-
tive models were fit, incorporating an interaction effect, for accesses, attendances and
admissions to check for variability according to hospital size. Additional models were
then fit to assess whether there was any variation in association of overall TOXBASE
use with rates of admission for 6 key drug subgroups: antidepressants, paracetamol,
antipsychotics, opioids (including all medicines, but excluding heroin), heroin and non-
opioid drugs of abuse.
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Results: Rates of TOXBASE use per Trust increased across the study period by 39.3%
(95%confidence interval [CI]=34.1%, 44.8%) in England and76.9% (24.7%, 151.0%) in
Wales, showing an increase in TOXBASE use which was substantially greater than the
increase in poisoning attendances. Admission rates exhibited seasonality, with lower
rates in January and February, increasing by 2.0% (1.0%, 3.1%) in England and 5.8%
(5.5%, 5.9%) inWales toward themiddle of the year. The initial model fit indicated that
the average proportion of poisoning patients admitted increased with both increas-
ing attendances and increasing TOXBASE use (England andWales overall, P < 0.0001;
England andWales excluding London, P< 0.0001; London, P< 0.0001). In England and
Wales overall, and in London alone, increased TOXBASE access to non-opioid drugs
of abuse advice was associated with a significant decrease in admissions (England and
Wales, −0.15% [−0.29%, −0.01%] [P = 0.032]; London, −1.02% [−1.53%, −0.50%]
[P < 0.0001]). In contrast, increased access to heroin advice was associated with a
significant increase in admissions in London (+2.03% [+0.11%, +3.99%] [P = 0.034]).
Increasing access to TOXBASE for paracetamol advice was associated with lower
admissions in England and Wales (England and Wales, −0.11% [−0.23%, −0.01%]
[P = 0.036]; England and Wales excluding London, −0.18% [−0.30%, −0.06%] [P =
0.001]) but higher admissions in London (+0.52% [+0.03%,+1.01%] [P= 0.035]).
Conclusions:Wehave shown that greater overall use of TOXBASE by hospitals is asso-
ciatedwith a higher proportion of poisoning attendances being admitted. Interestingly,
looking at particular drug groups, we found significant associations in both directions
between overall TOXBASE use and rates of admission for some drug groups. The cur-
rentmethodology is unable to determinewhether such decisionsmight be appropriate
or not.Mixed-methods research is now required to gain a better understanding of how
provision of poisons information affects decisions within the ED.
KEYWORDS
drugs of abuse, hospital activity analysis, pharmaceuticals, poisons information
1 INTRODUCTION
1.1 Background
Poisons information services aim to improve the care of patients with
suspected or confirmed poisoning. Theymay prevent unnecessary hos-
pital presentations (attendances) and are intended to improve triage
(decision whether to admit the patient to hospital or discharge from
the emergency department) and care of patients who do present to
hospital. When used by the public or primary care services, provi-
sion of poisons information reduces attendances at emergency depart-
ments and hospital admissions in both North America and the United
Kingdom.1,2
In the United Kingdom, the public is unable to access poisons infor-
mation directly from poisons information centers. TheNational Health
Service’s (NHS) introduction of telephone health information lines for
the general public in the early 2000s led to the need for a single
authoritative approach to poisons information provision for both pri-
mary and secondary care services.3 The UKNational Poisons Informa-
tion Service had launched its online clinical database TOXBASE in late
1999; it was subsequently adopted as the primary source of poisons
information for all healthcare services across the United Kingdom.4,5
TOXBASE is used routinely in the management of poisoned patients,
providing information, not only on the potential toxicity and treat-
ment of compounds, but also the dose thresholds for toxic effects and
required duration and nature of clinical monitoring. The database is
written and regularly updated by the National Poisons Information
Service clinical staff and has an editorial team with specialist advi-
sors and based on national and international published advice. It can
be searched for generic and common brand name products, particu-
larly medications. It also contains data on all types of poisoning. It is
the agreed standard of care in the United Kingdom. Where additional
information is required, healthcareworkers call a single national phone
number to be connected with poison information specialists and clini-
cal toxicologists at 1 of 4National Poisons Information Service poisons
information centers.
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Since 1999, use of TOXBASE has increased by >600% and contin-
ues to increase year by year. In 2017–2018, there were over 625,000
individual log-ons in the United Kingdom to the database, access-
ing in excess of 1.6 million product (agent) entries. Most (60%) came
from hospitals, although 30% came from primary care and ambu-
lance services.6 Most hospital enquiries come from emergency depart-
ments; TOXBASE accesses account for the vast majority of National
Poisons Information Service contacts from suchdepartments (354,678
in2016–2017 compared to<11,000 telephone enquiries). For this rea-
son, we concentrated our analysis on TOXBASE use.
1.2 Importance
Exploring howpoisons information services impact patient care in hos-
pital is challenging. Assessing how poisons information affects triage
and handling within hospital emergency departments themselves is an
important step in understanding, and auditing this interaction is key to
improving patient care and the use of poisons services in acute hos-
pitals. This is an important issue if poisons services are to be used
optimally and developed to respond to the needs of emergency physi-
cians. This project was undertaken as a first step in understanding how
current services are used, and how this might vary across the United
Kingdom.
1.3 Goals
The aim of this project was to evaluate the impact of poisons infor-
mation services on physician behavior. This is complicated, because
hospital activity varies both seasonally and geographically. In addition,
use of the TOXBASE database has increased over time.7 In England
and Wales (England and Wales), routine data are available on atten-
dances at emergency departments, with the broad clinical area of rea-
son for attendance described (eg, poisoning), and the proportion of
these attendances that are admitted.8,9 Hospital admissions activity is
coded using ICD10, but this coding is not yet applied to attendances.
In this study,weused routinely collecteddata onTOXBASEaccesses
from individual NHS Trusts (hospitals) to these pharmaceutical (drug)
products on TOXBASE and compared these to attendances, and admis-
sions towards fromtheED, from2008–2015.MostTOXBASEaccesses
(83%) from hospitals relate to pharmaceutical (drug) products, includ-
ing drugs of abuse. Using these data, we have explored the relationship
between frequency of overall use of TOXBASE and changes in rates
of admission as a proportion of attendances. In this way, we hoped to
begin to understand how the use of online poisons information ser-
vices in the United Kingdom might interact with clinician behavior as
reflected by hospital activity and admissions in order to design future
studies. An epidemiological study of this design shows associations,
which can then be the focus for further studies; it cannot establish cau-
sation. As online information systems are increasingly used inmedicine
this project may also inform others in the field.
The Bottom Line
Use of poison information services in emergency depart-
ments may impact admission decisions. Although greater
TOXBASE use in England and Wales was associated with
admission for poisoning overall, there was a decrease in
admission for non-opioid drugs of abuse and acetaminophen.
2 METHODS
2.1 Design
Data on the number of admissions and attendances for poisoning in
England and Wales for the period January 2008 to December 2015
were obtained from the Health and Social Care Information Centre
(HSCIC; https://digital.nhs.uk/) and from the NHS Wales Informatics
Service (http://www.wales.nhs.uk/nwis/home). These data were then
linked with data on the number of accesses made to the TOXBASE
database. ForWales, thiswas a straightforward taskof linkingbyhospi-
tal name. The linkage for the English data were more difficult, because
in some cases the hospital activity data were provided at individual
hospital level and in others it was provided at the NHS trust level
(an administrative unit), amalgamating data from 2 or more hospitals.
For consistency, all English hospital-level data were aggregated up to
NHS Trust level, which were linked with the relevant hospitals in the
TOXBASE data set.
2.2 Setting
This study was conducted using data available from routine NHS
data sources on attendance and admissions from hospital emergency
departments in the United Kingdom. We also assessed overall usage
of TOXBASE pharmaceutical product (agent) entries (including drugs
of abuse) as well as 6 commonmedicines and recreational drug groups:
antidepressants, paracetamol, antipsychotics, opioids (including all opi-
oid medicines but excluding heroin), heroin, and non-opioid drugs of
abuse. For simplicity, we refer to these together as “Drugs.” Heroinwas
assessed separately from opioids due to the major differences in its
supply and usage across the United Kingdom.
2.3 Selection
The data set used contained all data available to us for the study period
in England and Wales. Because poisoning attendances were not con-
sistently recorded in the early days of these NHS data systems, some
data were excluded from these analyses. Attendance reasons were not
recorded in Wales until April 2009, so all Welsh data prior to that
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date were eliminated from the analysis. In England, the reasons for
attendance at EDs (ie, poisoning) were not always consistently
recorded in some Trusts, and this was further complicated by merger
of hospitals into Trusts within the study period. Together, this resulted
in some large data gaps for poisoning attendances and resultant sharp
drops in the number of poisoning attendances recorded. Data within
these periods of unreliable recording were eliminated on a case-by-
case basis resulting in 4986 rows of data out of 13,990 rows being
omitted from the analysis; this amounted to only 2.8% of the total
number of attendances at A&E for poisoning (1,255,412). As a con-
sequence, data on 37.3% of TOXBASE accesses and 37.4% of hospi-
tal admissions could not be used indicating that the data quality issue
only affected emergency attendances to hospital. In total, the analysis
included data from 116 trusts out of 143 in England and 13 out of 17
inWales.
Data obtained from HSCIC in England were subject to the sup-
pression of small values (between 1 and 5) to keep individual patients
unidentifiable. To address this issue, we used a technique whereby
missing values were imputed empirically using a Bayesianmodel incor-
porating seasonality and long-term trend to estimate results in the
range of 1–5. Use of this methodmade allowance for hospital size (and
therefore workload) that meant that missing values for those hospi-
tals that were larger and consequently hadmostly complete data were
more likely to be imputed as 4 or 5, whereas those locations with a
large number of missing values were likely to be smaller hospitals and
somore likely to have smaller imputed values.
This study did not require approval by a UK Research Ethics Com-
mittee because the UK Health Research Authority has declared that
ethical approval is not needed for research studies that use information
collected routinely by anyUKadministration (England,Wales, Scotland
and Northern Ireland) as part of usual clinical care, provided this infor-
mation is passed to the researchers in a fully anonymized format.
2.4 Analysis
The seasonal and long-term trends in the rate of poisoning admis-
sions and the rate of TOXBASE accesses were explored using gener-
alized additive models, which allow for smoothly varying relationships
through time. The smooth terms and parameters in these models were
estimated via an iterative process. At each step, the terms were esti-
mated based on the response values minus the current estimates of
each other term in themodel, so that the values being used to estimate
the components were overall centered around zero but still retained
somepattern that is to be estimated, herein referred to as the centered
response. It is the final values of this iterative process that will be pre-
sented and interpreted as the trends in themodel.
The first model in this article examined the appropriateness of an
interaction term in examining the effect of TOXBASE use on admis-
sions. Themodel fit was of the form shown below:
E(log(yi)) = log(ai) + 𝛽0 + 𝛽1x1i + 𝛽2x2i + 𝛽3x1ix2i + f(ti) + g(mi). (1)
In this model, E(log (yi)) is the expected log number of admissions,
and log (ai) is the log number of poisoning attendances. The result
of this is that this model provides insight into the rate of poisoning
admissionsperpoisoning attendance, rather than thenumberof admis-
sions due to poisoning. We wanted to incorporate some measure of
hospital size in the model, hence the total number of attendances is
represented by x1i. The rate of TOXBASE access per attendance is
represented in the model using x2i, and x1ix2i denotes an interaction
between hospital size and TOXBASE accesses, which will account for
differences in the effect of TOXBASE access by hospital size. The final
2 terms represent the overall (f(ti)) and seasonal (g(mi)) patterns in the
rate of admissions per attendance. Positive values of β1 or β2 indicated
that admissions grow with attendances or accesses, whereas negative
values indicated a decrease in admissionswith attendances or accesses
respectively. The coefficient β3 of the interaction term indicated how
admissions change with attendances for different levels of TOXBASE
usage.
The above model was used as a starting point for the analysis
and was simplified where appropriate. These data exhibited over-
dispersion, a common artefact in count data, where the variance is
larger than the mean. This does not hold with the assumption of equal
meanandvariancedistributionmadebyuseof thePoissondistribution.
In order to account for this over-dispersion, a negative binomial model
was used.
Similar models were then used to summarize how the rate of admis-
sion varied in an average trust, with respect to the proportion of
accesses to the 6 aforementioned drug sub-groups. Thesemodels took
a simpler form as outlined in the following equation:
E(log(yi)) = 𝛽0 + 𝛽1xi. (2)
Here, yi is the proportion of attendances due to poisoning that
resulted in admission within each Trust, whereas xi is the proportion
of accesses made to the relevant drug group. Each drug group was
assessed independently, but the results will be presented as awhole. In
this analysis, we expect the coefficient β1 to be negative when increas-
ing proportions of accesses are associated with a decreasing propor-
tion of admissions.
Temporal changes were explored by fitting models for rates of
TOXBASE access and rates of admission by trust, through time. The
models were of the form:
E(log(y)) = 𝛽0 + 𝛽1 year. (3)
where y represents either the rate of access to TOXBASE or the rate
of admission due to drugs poisoning. The coefficient β1 was extracted
for admissions and accesses for each trust to give a measure of
the rate of change of TOXBASE use and admissions over time by
trust.
Due to the nature of the data, each model was fit on the log
scale, meaning that differences estimated from any of the above mod-
els are presented as multiplicative percentage changes. The results
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F IGURE 1 Plots showing the long-term and seasonal trends for TOXBASE accesses in grey (―) and poisoning admissions in black (―) for
England (A and C) andWales (B andD). The dashed lines represent 95% confidence intervals. For ease of comparison the data are shown related to
a centered response
section will also describe raw data, estimated regression coefficients
andmodel predictions where appropriate.
3 RESULTS
During the period studied, after accounting for issueswith data record-
ing, there were 1,220,857 attendances at hospital emergency depart-
ments in England andWales that were coded as due to poisoning. Dur-
ing the same period, 581,368 patients were admitted (46.5 per 100
attendances) due to overdose involving Drugs, and the relevant prod-
ucts pages within TOXBASE were consulted 2,629,846 times (2.15
accesses/attendance).
3.1 Long-term and seasonal trends
The seasonal and long-term trends in the rate of admissions due to
drugs poisoning and the rate of TOXBASE accesses/month are shown
in Figure 1 as a centered response. In England, the average Trust
had 1262 attendances, 639 admissions (50.6% of attendances), and
2205 TOXBASE accesses (1.75/attendance) in 2008. In 2015, the aver-
age number of attendances had increased to 1754 (39.0% increase),
with 762 admissions (19.2% increase; 43.4% of attendances) and 4165
TOXBASE accesses (88.9% increase; 2.37/attendance). In Wales, the
respective figures for 2009 were 425 attendances, 207 admissions
(48.7%of attendances) and 686 TOXBASE accesses (1.61/attendance);
by 2015, these had risen to 641 (50.8% increase), 291 (40.6% increase;
45.4% of attendances) and 2239 (326% increase; 3.49/attendance),
respectively.
Using the statistical models to look at the overall trend, the pro-
portion of attendances admitted decreased by 17.0% (14.3%, 19.6%)
in England between 2008 and 2015 compared to the non-significant
decrease of 4.9% (−23.0%, 13.2%) in Wales between 2009 and 2015.
TOXBASE usage, as a rate per poisoning attendance, in the statistical
models increased over the study period, by 39.3% (34.1%, 44.8%) in
England and 76.9% (24.7%, 151.0%) inWales.
We assessed whether the admission rate and the rate of TOXBASE
accesses per poisoning attendance showed seasonal variability. The
proportion of attendances admitted showed statistically clear sea-
sonal variability, with a peak in May in England and August in Wales
(Figure1); the seasonal peak in summer is equivalent to a small increase
in admissions of 2.0% (1.0%, 3.1%) in England, and 5.8% (5.5%, 5.9%)
in Wales from January. Seasonal variability also occurred in the vol-
umeof TOXBASEuse aswehave previously reported7; however, exam-
ining TOXBASE accesses per poisoning attendance to control for the
seasonal variability in attendances shows that there is no residual sea-
sonality in TOXBASE access.
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TABLE 1 Total number of attendances, poisoning-related admissions and TOXBASE accesses, in addition to the proportion of attendances
admitted and the rate of TOXBASE access per attendance for each region between 2008 and 2015
Region
Attendances
(n)
Poisoning-
Related
Admissions
(n)
Proportion of
admissions
TOXBASE
accesses
(n)
Rate of
TOXBASE
access per
attendance
NorthWest 241,883 119,105 0.492 553,592 2.289
Yorkshire and the Humber 183,263 82,582 0.451 387,800 2.116
South East 163,955 84,843 0.517 328,887 2.006
London 150,815 42,808 0.284 246,445 1.634
WestMidlands 124,769 57,051 0.457 239,882 1.923
East of England 95,617 53,290 0.557 250,536 2.62
SouthWest 82,753 45,160 0.546 168,682 2.038
EastMidlands 73,586 41,455 0.563 189,344 2.573
North East 56,303 32,460 0.577 130,550 2.319
Wales 47,913 22,614 0.472 134,128 2.799
Total 1,220,857 581,368 0.476 2,629,846 2.154
F IGURE 2 "Heat" maps showing the variation in the proportion of poisoning attendances admitted and the rate of TOXBASE accesses per
poisoning attendance. Darker areas represent higher activity
3.2 Regional variability
We then investigated regional variability in the proportion of poison-
ing attendances admitted and in the rate of TOXBASE accesses per
poisoning attendance across England and Wales. This was done by
examining NHS Regional level maps of the data. These NHS Regions
were changed during the period covered by the study to a much
larger number of smaller areas run by NHS Clinical Commissioning
Groups. For simplicity, we have used the older regional classification.
Overall rates of admission and TOXBASE access per attendance were
calculated as the total number of admissions or accesses in that region,
over the entire period, divided by the total number of attendances due
to poisoning in that region over the entire period.
We found there to be little variability in the proportion of poisoning
attendances who were admitted, other than for London. Over the
entire study period, the proportion of attendances admitted from Eng-
land andWales regions outside London ranged from0.451 in Yorkshire
and the Humber region to 0.577 in the North East region (Table 1;
Figure 2) compared to 0.284 in London. The rate of TOXBASE accesses
per poisoning attendance within England varied from 1.923 in the
West Midlands to 2.620 in the East of England, with London again low
at 1.634 andWales high at 2.799 (Table 1; Figure 2).
From these data, it is clear that the pattern of poisoning admissions
and TOXBASE accesses is different in London compared to the rest
of England andWales. Specifically, both the proportion of attendances
admitted and the rate of TOXBASE accesses per poisoning attendance
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TABLE 2 Model coefficients for the effect of hospital attendances, TOXBASE accesses and the interaction of these attendances and accesses
on hospital admission due to drugs poisoning for each of England andWales overall, England andWales excluding London and London only. These
coefficients were estimated after accounting for temporal trends in admissions
England andWales
overall
England andWales
excluding London London
Attendances −2.570× 10−5
SE 1.57× 10−6
P< 0.0001
−2.069× 10−5
SE 1.92× 10−6
P< 0.0001
−3.453× 10−5
SE 3.55× 10−6
P< 0.0001
TOXBASE accesses 0.1107
SE 4.48× 10−3
P< 0.0001
0.1198
SE 4.58× 10−3
P< 0.0001
0.0565
SE 2.04× 10−2
P< 0.0001
Attendances× TOXBASE
accesses
4.073× 10−6
SE 4.52× 10−7
P< 0.0001
2.931× 10−6
SE 4.76× 10−7
P< 0.0001
8.405× 10−6
SE 1.77× 10−6
P< 0.0001
TABLE 3 Estimated coefficients for the effect of hospital size (as measured by the total number of attendances) and the rate of access to
TOXBASE on the rate of admission due to poisoning per poisoning attendance after accounting for temporal trends
England and
Wales overall
England and
Wales excluding
London London
Total attendances −1.719× 10−5
SE 1.28× 10−6
P< 0.0001
−1.354× 10−5
SE 1.55× 10−6
P< 0.0001
−2.185× 10−5
SE 2.49× 10−6
P< 0.0001
Rate of access to TOXBASE 0.1447
SE 0.0025
P< 0.0001
0.1435
SE 2.58× 10−3
P< 0.0001
0.1438
SE 9.14× 10−3
P< 0.0001
are lower in London than in the other regions. One possible explana-
tion for the difference in Londonmay be relative excess of medical stu-
dents, but this would be expected to cause more TOXBASE accesses
per admission, not the fewerwe saw. This observeddifferencemay also
be related to some London hospitals following different protocols for
treating poisoned patients, and this prompted the decision to further
assess trends in 3differentways: England andWales overall, in England
andWales without London and London alone.
3.3 Interaction models
We then assessed the relationship between rate of TOXBASE use
per poisoning attendance and the rate of admissions due to drugs
poisoning per poisoning attendance. This was initially done using the
interaction model outlined in Equation 1, which took account of the
effect of overall attendances on the rate of admissions, to investigate
whether the effect of TOXBASE use varied depending on hospital size.
We found that the interaction term in the model was 4.073 × 10−6
(standard error (se) 4.515 × 10−7), P < 0.001. This implies that were
large hospitals to increase their rate of accesses to TOXBASE the pre-
dicted increase in the admission rate is proportionately higher than in
a smaller hospital which increases its access rate. However, the mag-
nitude of this effect is minor as evidenced by the estimated coeffi-
cient, given the magnitude of the coefficient of the main effect of the
TOXBASE access rate (Table 2).
For the data overall, the model including the interaction term
resulted in 75.4% of the variance in the observed data being
explained—this was only a marginal improvement over the model
excluding the interaction term, which had 75.2% variance explained.
These results were similar for the data excluding London and for Lon-
don individually. This indicates that the interaction effect does not con-
tribute a great deal to the fit of themodel, and for simplicity, themodel
excluding this interaction will be presented here.
We found that the rate of admissions due to poisoning (per poison-
ing attendance) tended to decrease as hospital size increased, as indi-
cated by the negative estimate of the coefficient in the first row of
Table 3. This decrease is such that for every 100 additional attendances
the rate of admissions per poisoning attendance would decrease by
≈0.2%.
In addition, there was an increase in the rate of poisoning admis-
sions with an increasing rate of access to TOXBASE. This increase
was such that for every additional TOXBASE page accessed per poi-
soning patient, there was a 15.6% (95% confidence interval [CI] =
15.0%, 16.1%) increase in the rate of poisoning admissions per poison-
ing attendance. The size of this effect was similar across all 3 of the
regional configurations examined (see Table 2; positive coefficient in
the second row).
These models were additionally fit for each year to investigate
whether the relationship between TOXBASE use and attendances was
stable over the period of the study. With the exception of 2008, dur-
ing which there were no observations for Welsh hospitals, and English
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F IGURE 3 Plot showing the relationship between the rate of poisoning admissions per poisoning attendance and the rate of TOXBASE use per
poisoning attendance. Groups of points are separated by colour to extract the relationship bymonth within each year
data not particularlywell recorded, therewas very little variation in the
estimated coefficients by year (Supporting Information Table S1).
The positive association between TOXBASE use and admissions
described by the model coefficients seems counterintuitive, given the
opposing trends in the rate of admission and the rate of TOXBASE
use seen in Figure 1. Further exploration of this is shown in Figure 3,
which plots the rate of admissions per poisoning attendance against
the rate of TOXBASE access per poisoning attendance. The data have
been aggregated over trusts, so that each point in the plot corresponds
to a month of data. The points are colored based on which year the
data were observed in, and it can be seen that points observed in
earlier years tend to be on the left-hand side of the plot, with later
years sitting on the right-hand side of the plot. There is, overall, a
decreasing trend in these observations, which is due to the overall
temporal pattern, where the average rate of admission has decreased
over time.
Examining individual groups of points, it can be seen that, particu-
larly in recent years, there is positive correlation between the rate of
admission and the rate of TOXBASE access per poisoning attendance.
It is thiswhich is driving the positive coefficient for TOXBASEuse in the
models above (Tables 2 and 3).
Models were fit for each individual trust for the rate of TOXBASE
accesses and the rate of admissions due to drug poisoning against year
to get an estimate of the annual rate of change. These trust-level coef-
ficients were used to find those trusts that had the largest decrease
in TOXBASE use through time, the largest increase in TOXBASE use
through time, and the smallest change in TOXBASE use through time.
The top 5 in each casewere taken, and the rate of admission due to poi-
soning was plotted against the rate of TOXBASE access per poisoning
attendance. The coefficients for the relationship between admission
and access rates in thosewith the largest increase, the smallest change,
and the largest decrease in TOXBASE use were (coefficient [se]): 0.049
(0.020), 0.109 (0.022) and 0.203 (0.027), respectively. This indicates
that for those hospitals in which TOXBASE use has decreased most,
the rate of admissions reduced more than the comparative increase in
admissions in those hospitalswhoseTOXBASEuse increasedmost, fur-
ther emphasising an interaction between TOXBASE use and admission
rates with poisoning.
This finding is suggestive of a link between TOXBASE use and triage
admission decisions for poisoned patients. However, this analysis can-
not determine whether TOXBASE use is changing decisions on admis-
sion or whether more severe cases that require admission result in
more TOXBASE use. To explore this aspect in more detail, we under-
took modelling of common drug groups, to compare the patterns of
TOXBASEagent accesses for these drugswith theoverall proportion of
poisoning patients admitted inNHSTrusts,whichmight lead to abetter
understanding of the impact of TOXBASE. We reasoned that, if these
drug groups varied in their effects on admission, this might indicate an
effect deriving from TOXBASE advice.
3.4 Drug group specific modelling
We did not have access to diagnostic coding for attendances or admis-
sions, preventing us from relating drug-specific TOXBASE accesses to
attendances and admissions for that same drug. However, we obtained
drug group TOXBASE access data for 6 important drug groups (antide-
pressants, paracetamol, antipsychotics, opioid medicines [excluding
heroin], heroin, and non-opioid drugs of abuse, Table 4) and com-
pared it with the overall proportion of poisoning admissions per
Trust. Across groups, we noted regional variation in TOXBASE
accesses, with London often being high or low for the proportion
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TABLE 4 Number of accesses to TOXBASE entries on pharmaceuticals overall and to selected drug classes during the study period byUK areas
England and
Walesoverall(%)
England andWales
excluding London(%) London(%)
All drug accesses 2,184,507 1,985,033 199,474
Antidepressants 370,657 (17.0) 341,922 (17.2) 28,735 (14.4)
Paracetamol 323,308 (14.8) 294,449 (14.8) 28,859 (14.5)
Non-opioid drugs of abuse 150,040 (6.87) 133,252 (6.71) 16,788 (8.42)
Opioids 141,069 (6.45) 130,612 (6.58) 10,457 (5.24)
Antipsychotics 125,698 (5.75) 113,912 (5.74) 11,786 (5.91)
Heroin 15,786 (0.72) 13,992 (0.70) 1,794 (0.90)
Each cell contains the number of accesses. The percentage of accesses is displayed in parentheses where appropriate.
TABLE 5 Individual effects of accesses to TOXBASE on the rate of change in admissions as presentations for 6 common drug sub-groups for
England andWales combined, England andWales excluding London, and London trusts only
England and
Walesoverall
England andWales
excluding London London
Antidepressants +0.01%
(−0.11%,+0.14%)
+0.04%
(−0.09%,+0.17%)
−0.21%
(−0.71%,+0.30%)
Paracetamol −0.11%
(−0.23%,−0.01%)a
−0.18%
(−0.30%,−0.06%)a
+0.52%
(+0.03%,+1.01%)a
Non-opioid drugs of abuse −0.15%
(−0.29%,−0.01%)a
−0.04%
(−0.19%,+0.10%)
−1.02%
(−1.53%,−0.50%)a
Antipsychotics +0.00%
(−0.19%,+0.20%)
+0.07%
(−0.14%,+0.28%)
−0.49%
(−1.21%,+0.24%)
Opioids −0.02%
(−0.22%,+0.17%)
+0.03%
(−0.17%,+0.23%)
−0.59%
(−1.41%,+0.23%)
Heroin +0.44%
(−0.15%,+1.03%)
+0.16%
(−0.45%,+0.78%)
+2.03%
(+0.11%,+3.99%)a
The values shown are the percentage change in admissions for every increase of 1 attendance. aSignificant effects.
of accesses to each drug group (Table 4, Supporting Information
Table S1).
Models were fit to assess the effect of TOXBASE access rates on
admissions for these drug groups. The effects of the drugs categories
on admission were in some cases quite different between London and
elsewhere in England andWales (Table 5). In England andWales over-
all, and in London alone, increased accesses to TOXBASE advice on
non-opioid drugs of abuse (as a proportion of all TOXBASE accesses)
were associated with a statistically significant decrease in admissions
per attendance (England and Wales, −0.15% [−0.29%, −0.01%], P =
0.032; London, −1.02% [−1.53%, −0.50%], P = 9.2 × 10−5). Increased
access to heroin advice was associated with a significant increase
in admissions in London (+2.03% [+0.11%, +3.99%], P = 0.034) but
not elsewhere in England and Wales. Increased access to the parac-
etamol TOXBASE entry was associated with a significant reduction
in admissions in England and Wales overall and England and Wales
excluding London (England andWales, −0.11% [−0.23%, −0.01%], P =
0.036; England andWales excl. London,−0.18% [−0.30%,−0.06%], P=
0.001) but increased admissions in London (+0.52% [+0.03%,+1.01%],
P= 0.035).
4 DISCUSSION
In this paper, we examined the interaction between hospital activity—
specifically the decision to admit a poisoned patient attending the
emergency department—and the level of use of the online poison infor-
mation service TOXBASE. We used statistical models for this analy-
sis, to account for underlying national changes over time of the use of
the TOXBASE database, poisoning attendances, and admissions from
the emergency department to hospital wards. The United Kingdom
runs a health care system (NHS) that is free at pointofcare and is fully
funded by taxation. There are no private facilities included in this anal-
ysis and effectively none in the United Kingdom in any case. Patients
may, as elsewhere, self-present to an ED, present after consultation
with a doctor/pharmacist or generic health information telephone
line (NHS111 in UK) or after calling an ambulance directly. Although
these data do not allow us yet to understand the interaction of poi-
sons information and management at an individual patient level, being
designed to give an overview of the interactions between database use
and triage at a national, regional and drug category level across Eng-
land and Wales, they are essential for describing and understanding
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the situation before conducting any further mixed-methods research
analysis.
The use of an internet database by clinicians is not equivalent to
telephone enquiries, in that >1 access may be made to an individ-
ual database drug entry for individual patients. Thus, access rates do
not equate to patients, and more complex poisoning cases may result
in more database accesses than simpler ones. It is not possible for
us to differentiate duplicate enquiries from single enquiries about a
patient. Because the number of telephone calls from UK hospitals to
the National Poisons Information Service were orders of magnitude
less than TOXBASE use, only 3% of the National Poisons Information
Service enquiries coming from hospital emergency departments are
by telephone, they are unlikely to impact this analysis. The approach
we have used is intended to address this by overall modelling of total
database activity, and patient handling is unlikely to be unique to
individual hospitals or regions of the United Kingdom. We included
large numbers of TOXBASE enquiries and related them to hospital
activity.
Thesemodels show clear interactions on a population level between
the usage of poisons information services and hospital activity. For any
given level of activity (number of poisoning attendances), the number
of patients admitted directly relates to the number of times TOXBASE
is accessed.Higher ratesofTOXBASEaccess areassociatedwithhigher
rates of poisoned patient admissions, especially in larger hospitals.
These interactions seemed stable across all years studied, apart from
2008 when data from the Welsh system was unavailable and English
data markedly incomplete (Supporting Information Table S1). Compar-
ing hospitals based on their change in TOXBASE use over time indi-
cated that, in the hospitals where the usage of TOXBASE decreased
most over the study period, there was a larger relative decrease in the
rate of admissions compared to the increase in admissions in those hos-
pitals whose TOXBASE use increased. These analyses further support
interactions between TOXBASE use and admission rates as they show
clear relationships between hospital activity and changes and usage of
poisons information in TOXBASE.
It is possible that higher TOXBASE use is due tomore complex cases
being seen and admitted, and the database being accessed more often
by multiple clinical teams involved in the treatment of these patients.
However, because this methodology does not determine causality,
we cannot ascertain if the increased admission rate per attendance
associated with increased TOXBASE use represents improved patient
management or is caused by an unknown confounder. Although the
increased use of a poison information facility could affect admissions,
further work is required to assess if the increases in admissions we
observedare clinically appropriate.Unfortunately, national attendance
data are not coded accurately enough for us to account for the influ-
ence of attendance case-mix on proportion of cases admitted.
We addressed this problem in attendance coding by reasoning that
analysis of TOXBASE accesses to groups of different pharmaceuticals
could act as a surrogate for case-mix. If use of TOXBASE was entirely
driven by hospital activity, then the relationship between admissions
and ED accesses to relevant TOXBASE pages would be consistent. In
contrast, if TOXBASE influenced clinical decisionmaking, one would
expect the relationship between specific TOXBASE access and admis-
sions to bemore complex—the situation revealed in this analysis. Inter-
estingly we found both positive and negative relationships between
admissions andTOXBASE accesses for different drug groups and in dif-
ferent regions. Increased rates of access to non-opioid drugs of abuse
were associated with reduced admissions, whereas increased access
to paracetamol information was associated with increased admissions
in London but reduced admissions in the rest of England and Wales.
Thus, although it might be assumed that staff might be familiar with
common poisoning such as paracetamol and only use TOXBASE for dif-
ficult patients, there are several points in the management pathway
where reference to TOXBASEmight be useful, such as reviewing blood
test results and decisions on further treatment or discharge. Increased
access to heroin information was associated with an increase in admis-
sions in London only.
These findings are compatible with clinical decisionmaking being
related to TOXBASE advice with the observed data being what one
might expect if poisons advice aided triage of some patient groups,
enabling early safe discharge of some, and requiring further observa-
tion of others, with admission. Although we cannot definitively con-
firm this due to lack of data on presentation medication ingestion, we
believe this themost plausible explanation.
The data on paracetamol are unexpected and may relate to some
clinicians accessing TOXBASE for all paracetamol poisoning due to the
complexity of advice since the 2012 regulator’s new advice on parac-
etamol management,10 and in particular use of local management pro-
tocols, such as we have previously described.11
The patterns of attendances and TOXBASE use are different in Lon-
don compared to the rest of England and Wales. These findings are in
linewith the regional differenceswehavepreviously found inparaceta-
mol poisoning admissions12 andwith different patterns of use of drugs
of abuse across the United Kingdom.13 London is the NHS Region with
least TOXBASE use and fewest admissions for poisoning. Although
the current data on hospital attendances are insufficiently detailed to
allow any further exploration of this finding, possible explanationsmay
include the high proportion of Englishmedical schools based in London
(7 of 25 total) and a difference in experience or confidence of ED staff.
Other possibilities are differences in epidemiology of poisoning, local
practice or the way TOXBASE is used between London and elsewhere
in England andWales. Further research will require more data on indi-
vidual case-mix and severity, as well as direct observational studies of
TOXBASE use. However, these differing patterns and trendswithin dif-
ferent UK regions are compatible with a direct effect of poisons infor-
mation on clinician behavior.
Going forward, we believe these data have the potential to be used
for audit of performance of individual units as a tool for public health,
and to do that, optimally, we would need data on presentation inges-
tions to be included, which is not presently the case. This has also
prevented analysis of admissions as a proportion of presentations for
specific drugs. This is one reason we are unable to assess the reasons
for different patterns in London and the rest of the United Kingdom.
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Such informationwould also better support policy inmanaging poison-
ing in the United Kingdom.
5 LIMITATIONS
The paper is limited by our inability to show causality. However,
because we show that the rates of admission are related to TOXBASE
use at Trust level, and these effects are significant at the national level,
the association has face validity.
Data had to be excluded from the analysis due to incompleteness or
to inconsistency in theway attendance reasonswere recorded.We are
dependent on hospital coding for our analyses, with discharge coding
being used in the case of admission. A proportion of coding errors are
likely to have occurred in all hospitals but are unlikely to have affected
our conclusions; furthermore, detailed analysis of discharge coding has
suggested these are generally>95% accurate.14
We have not considered the effect of National Poisons Informa-
tion Service’s telephone information services, which are available 24/7
to support clinicians managing more complex poisoning. However,
because at least 97% of poison information enquiries from EDs come
via the internet and TOXBASE, differences in telephone call numbers
cannot explain the significant differences we have observed. It is also
likely that most triage decisions occur after review of TOXBASE advice
and not after a phone call, because these tend to deal with specific
treatment advice.6
The hospital attendance and admission data did not contain infor-
mation on the agents involved, which may have confounded the
analysis, particularly for smaller hospitals that receive fewer cases and
do not tend to handle complex cases poisoning. However, as the data
in England pertain to trusts, differences in case mix should have been
averaged out. The imputation of small numbers could potentially add
error, but this isminimizeddue to the inclusionofmanyof these smaller
hospitals within the larger Trusts used in our analysis.
Finally, in the drug group-level analysis, access to specific drug
groups on TOXBASE was used to describe the trend in drugs poison-
ing overall. A better comparison could be made if data were available
on admissions and attendances due to poisoning by each specific drug
group. However, even if the data were available, the number of admis-
sions and attendances would be small, requiring a large amount of
data suppression to maintain patient confidentiality, markedly reduc-
ing usability.
6 CONCLUSIONS
In summary, we have shown that increased hospital use of an internet-
based poisons information database, TOXBASE, is associated with an
increase in overall admission rates overall, but rates of access to par-
ticular drug groups differ in their relationships with admission rates.
These findings suggest a possible direct effect of TOXBASE on clin-
ician behavior and patient management decisions and highlight the
potential use of point-of-care internet poisons information systems.
Further mixed-methods research is required to obtain better evidence
on how TOXBASE is used in EDs and how it might affect clinical
practice.
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